reports
General Dynamics Corp: 1 director
A director at General Dynamics Corp sold/sold after exercising options 9,102 shares at 286.040USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offe...
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share of...
Kirby Corp: 2 directors
A director at Kirby Corp sold 3,750 shares at 109.250USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Tyson Foods To Participate in 19th Annual BMO Global Farm to Market Co...
Tyson Foods To Participate in 19th Annual BMO Global Farm to Market Conference SPRINGDALE, Ark., May 02, 2024 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) announced today that management will participate in the 19th Annual BMO Global Farm to Market Conference on May 15, 2024 in New York City. The fireside chat with Donnie King, president & CEO, and John R. Tyson, executive vice president & CFO, will begin at approximately 8:00 a.m. Eastern Time and will be available via a live webcast. The webcast link, replay, and other information can be accessed on the company’s investor relations...
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2024 was $40.3 million, compared to product revenue, net of $46.8 million in the first quarter of 2023. Based on accounting principles generally accepted in the Un...
Pilgrim’s Pride Reports First Quarter 2024 Results with $4.4 Billion i...
Pilgrim’s Pride Reports First Quarter 2024 Results with $4.4 Billion in Net Sales and Operating Income of $250.3 Million GREELEY, Colo., May 01, 2024 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC), one of the world's largest poultry producers, reports its first quarter 2024 financial results. First Quarter Highlights Net Sales of $4.4 billion.Consolidated GAAP operating income margin of 5.7%.GAAP Net Income of $174.9 million and GAAP EPS of $0.73. Adjusted Net Income of $182.9 million or Adjusted EPS of $0.77.Adjusted EBITDA of $371.9 million, or a 8.5% margin, with adjus...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Are the Lows "In" for this Pullback? While we are not yet out of the woods, we continue to see evidence that suggests the lows may be "in" for this pullback. Last week (4/23/24 Compass) we discussed the possibility that further downside was limited on the S&P 500 due to a multitude of reasons (SPX had simply filled 2/22/24 gap support that we had been discussing since late-February, Russell 2000 and Equal-Weighted S&P 500 were holding above key supports, short-term oversold conditions, subdued ...
SUM SUMMIT MATERIALS INC. CLASS A
MATX MATSON INC.
SBL SAFE BULKERS INC.
GNK GENCO SHIPPING & TRADING LTD.
LCM COSTAMARE INC.
MLM MARTIN MARIETTA MATERIALS INC.
AWC BROOK CROMPTON HOLDINGS
CENX CENTURY ALUMINUM COMPANY
KEX KIRBY CORPORATION
NMM NAVIOS MARITIME PARTNERS
GSL GLOBAL SHIP LEASE INC. CLASS A
VNC VRANCART
DAC DANAOS
KNF KNIFE RIVER CORPORATION
HSHP HIMALAYA SHIPPING LTD.
HWM HOWMET AEROSPACE INC COM
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and ...
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United Sta...
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) C...
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the im...
Farmer Brothers to report fiscal third quarter 2024 financial results
Farmer Brothers to report fiscal third quarter 2024 financial results NORTHLAKE, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Farmer Brothers (NASDAQ: FARM) announced today the company will publish its fiscal third quarter 2024 financial results for the period ended March 31, 2024 with the filing of its 10-Q and the issuing of its quarterly shareholder letter, both of which will be posted on the section of its website after the close of market Thursday, May 9. The company will also host an audio-only investor conference call and webcast at 5 p.m. Eastern on Thursday, May 9 to provide a rev...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Quad/Graphics, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 April 2024 in which Moody's reassessed the appropriateness of the ratings in the con...
Kirby Corporation Announces 2024 First Quarter Results
Kirby Corporation Announces 2024 First Quarter Results First quarter 2024 earnings per share of $1.19Inland marine experienced strong market conditions with a sequential increase in spot market prices and high-teens operating margins despite a sequential increase in delay daysCoastal operating margins improved to high single to low double-digit rangeBreaking out power generation at KDS as its significance continues to grow, constituting 41% of KDS revenues Kirby repurchased 498,505 shares at an average price of $83.82 for $41.8 million in the 2024 first quarterAcquired 13 barges, including ...
John B. Sanfilippo & Son, Inc. 3rd Quarter Fiscal Year 2024 Operating ...
John B. Sanfilippo & Son, Inc. 3rd Quarter Fiscal Year 2024 Operating Results Conference Call Elgin, IL, April 24, 2024 (GLOBE NEWSWIRE) -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products, will hold its quarterly conference call to discuss its third quarter fiscal year 2024 operating results on Thursday, May 2, 2024 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Third quarter fiscal 2024 results are expected to be released after the market closes on Wednesday, May 1, 2024. To register for the call, please click...
Abeona Therapeutics Provides Regulatory Update on Pz-cel
Abeona Therapeutics Provides Regulatory Update on Pz-cel Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and submitting requested CMC information in 3Q 2024 Conference call and webcast on Tuesday, April 23, 2024 at 8:30 a.m. ET to provide details on the requested CMC information CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq...
Puma Biotechnology to Host Conference Call to Discuss First Quarter 20...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of th...
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles. M...
Pilgrim’s Pride Corporation to Host First Quarter Earnings Call on May...
Pilgrim’s Pride Corporation to Host First Quarter Earnings Call on May 2, 2024 GREELEY, Colo., April 10, 2024 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its first quarter 2024 financial results after the U.S. market closes on Wednesday, May 1. The company’s executives will review the results on a conference call and webcast on Thursday, May 2, 2024 at 7 a.m. MT (9 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with Pilgrim’s executive management te...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.